Compare Apple Inc (AAPL) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Sanofi SA — how do they compare? Apple Inc trades at $313.14 (market cap $4.56T), while Sanofi SA trades at $42.85 (market cap $103.29B). The key difference: Apple Inc is far larger — about 44.1× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.63%). Which is the better fit depends on your goals.
| AAPL | SNY | |
|---|---|---|
Market Cap | $4.56T | $103.29B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $52.34 |
52-Week Low | $202.38 | $41.33 |
Enterprise Value | $4.58T | $119.78B |
Dividend Yield | 0.35% | 5.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $313.28, up 0.2% on the day, with a bullish technical signal and strong support at $309. Recent earnings beats and a 26.91% net margin in 2025 highlight robust profitability. Revenue grew to $416.16B in 2025, with further growth projected to $451.4B in 2026. Positive news includes leading smartphone shipments and institutional buying, though union-busting allegations and potential Q2 2026 earnings miss pose concerns.
Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Strengths include high margins, cash flow generation, and AI opportunities via 2.5B device base. Risks involve competitive pressures, regulatory scrutiny from EU fines, and reliance on iPhone sales. Analyst sentiment is bullish (63% buy ratings), but investors should monitor execution against earnings expectations.
SNY trades at $42.98, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results with EPS of $1.10 beating expectations of $1.06, continuing a trend of positive surprises. Revenue grew to $46.72 billion in 2025 with net income margin improving to 16.72%. Recent developments include EU approval for Cenrifki in multiple sclerosis and FDA approval for Tzield expansion in pediatric diabetes treatment.
SNY presents a mixed investment case with solid fundamentals offset by technical weakness. The stock trades at reasonable valuations (P/E 18.9, P/S 1.92) with strong profitability metrics, but faces near-term headwinds from an antitrust probe and bearish technical indicators. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism amid regulatory uncertainties and pipeline execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
